Different clinical significance of FGFR1–4 expression between diffuse-type and intestinal-type gastric cancer

Table 1 Clinicopathological factors and expressions of FGFR1 to FGFR4 in DGC

		FGFR1			FGFR2			FGFR3			FGFR4
		Low	High	p	Low	High	p	Low	High	p	Low	High	p
	n	69	40		56	53		44	65		21	88
Age (years)
< 65	61	45	16	0.011	37	24	0.029	24	37	0.81	15	46	0.11
≥ 65	48	24	24	0.011	19	29	0.029	20	28	0.81	6	42	0.11
Gender
Female	40	25	15	0.90	22	18	0.56	11	29	0.037	8	32	0.88
Male	69	44	25	0.90	34	35	0.56	33	36	0.037	13	56	0.88
Main location
Middle or lower	83	54	29	0.50	46	37	0.13	28	55	0.012	16	67	1.00
Upper	26	15	11	0.50	10	16	0.13	16	10	0.012	5	21	1.00
Depth of invasion
Early (T1)	35	29	6	0.004	26	9	0.001	18	17	0.11	12	23	0.006
Advanced (T2/3/4)	74	40	34	0.004	30	44	0.001	26	48	0.11	9	65	0.006
LN metastasis
Negative (N0)	45	35	10	0.009	30	15	0.007	19	26	0.74	16	29	<0.001
Positive (N1/2/3)	64	34	30	0.009	26	38	0.007	25	39	0.74	5	59	<0.001
Stage
I	43	36	7	<0.001	30	13	0.002	21	22	0.15	16	27	<0.001
II/III/IV	66	33	33	<0.001	26	40	0.002	23	43	0.15	5	61	<0.001
Distant metastasis or recurrence
Negative	67	50	17	0.002	43	24	0.001	28	39	0.70	18	49	0.01
Positive	42	19	23	0.002	13	29	0.001	16	26	0.70	3	39	0.01
Peritoneal dissemination
Negative	82	58	24	0.005	46	36	0.086	35	47	0.39	18	64	0.22
Positive	27	11	16	0.005	10	17	0.086	9	18	0.39	3	24	0.22
Hematogenous metastasis
Negative	106	67	39	1.00	56	50	0.11	42	64	0.56	21	85	1.00
Positive	3	2	1	1.00	0	3	0.11	2	1	0.56	0	3	1.00
HER2 score
0–1	106	68	38	0.56	55	51	0.61	43	63	1.00	21	85	1.00
2–3	3	1	2	0.56	1	2	0.61	1	2	1.00	0	3	1.00

ISSN: 1477-7819